RENAL-AF trial: Apixaban similar to warfarin

The RENAL-AF trial showed that apixaban 5 mg twice daily results in similar rates of bleeding and stroke as warfarin among patients with end-stage renal disease on haemodialysis. This randomised controlled trial assessed the safety and efficacy of apixaban as a means for stroke prophylaxis among patients with atrial fibrillation (AF) and end-stage renal disease on haemodialysis, but it was terminated early due to slow enrolment. Dr Sean Pokorney (Duke Clinical Research Institute, USA) presented the interim trial results, which included data on 154 patients with AF and end-stage renal disease who received renal replacement therapy by haemodialysis and who were candidates for oral anticoagulants. Patients were randomised to either apixaban 5 mg twice daily (n=82; 29% received 2.5 mg twice daily) or warfarin (n=72). The mean age of patients in both arms was 69 years; 35% were female. Nearly 20% of ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 26 February, 2020